Substance / Medication

Tositumomab

Overview

Active Ingredient
tositumomab
RxNorm CUI
263010

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Phase 2 Study of Iodine-131 Tositumomab Plus Chemotherapy in Patients With Previously Untreated Mantle-Cell Lymphoma.
Zelenetz Andrew D, Popplewell Leslie L, Noy Ariela et al. · Clin Lymphoma Myeloma Leuk · 2020
PMID: 32800518TrialFull text (PMC)
Initial Experience with Tositumomab and I-131-Labeled Tositumomab for Treatment of Relapsed/Refractory Hodgkin Lymphoma.
Jacene Heather, Crandall John, Kasamon Yvette L et al. · Mol Imaging Biol · 2017
PMID: 27798787Trial
Patients with relapsed follicular lymphoma treated with rituximab versus tositumomab and iodine I-131 tositumomab.
Quackenbush Robert C, Horner Thierry J, Williams Vanessa C et al. · Leuk Lymphoma · 2015
PMID: 24898665Trial
Tumor-Absorbed Dose Predicts Progression-Free Survival Following (131)I-Tositumomab Radioimmunotherapy.
Dewaraja Yuni K, Schipper Matthew J, Shen Jincheng et al. · J Nucl Med · 2014
PMID: 24842891TrialFull text (PMC)
R-CHOP with iodine-131 tositumomab consolidation for advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0433.
Friedberg Jonathan W, Unger Joseph M, Burack W Richard et al. · Br J Haematol · 2014
PMID: 24749780TrialFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Tositumomab (substance)
SNOMED CT
407318006
UMLS CUI
C0879399
RxNorm CUI
263010

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.